GlaxoSmithKline reported GBP6.16B in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
AbbVie USD 5.13B 78M Jun/2026
Alcon AG USD 2.44B 47M Mar/2026
Almirall EUR 178.13M 1.54M Dec/2025
Amgen USD 6.22B 34M Jun/2026
argenx SE USD 473.53M 132.91M Dec/2025
AstraZeneca USD 6.93B 362M Jun/2026
Bayer EUR 12.01B 321M Mar/2026
Biogen USD 2.38B 435.3M Jun/2026
Bristol-Myers Squibb USD 2.74B 19M Jun/2026
Eli Lilly USD 16.79B 2.26B Jun/2026
Fresenius EUR 2.73B 119M Mar/2026
Fresenius Medical Care EUR 2.3B 162.24M Mar/2026
Genmab DKK 21M 8M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
GlaxoSmithKline GBP 6.16B 233M Mar/2026
Glaxosmithkline GBP 6.16B 39M Mar/2026
GRIFOLS EUR 3.49B 34M Jun/2026
Hikma Pharmaceutical USD 1.11B 24M Dec/2025
Lakefront Biotherapeutics EUR 17.69M 4.8M Mar/2026
Lonza CHF 1.68B 163M Dec/2025
Merck EUR 4.78B 220M Mar/2026
Merck USD 6.48B 179M Mar/2026
Novartis USD 6.22B 66M Jun/2026
Novo Nordisk DKK 45.65B 21.26B Jun/2025
Orion EUR 512.2M 55.9M Mar/2026
Pfizer USD 9.94B 722M Jun/2026
Philips EUR 3.22B 106M Jun/2026
Recordati EUR 550.34M 4.52M Jun/2026
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 24.12B 620M Jun/2026
UCB EUR 1.31B 173M Dec/2024